| Methods |
4‐week placebo run‐in; inclusion criteria= supine and standing DBP 95‐115 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
Trandolapril 0.5 mg: n=41(17 males,24 females); mean age=49(13) years; baseline SBP=163.8(12.8) mm Hg, DBP=99.5(5.8) mm Hg;
Trandolapril 1 mg: n=42(8 males,38 females); mean age=48(13) years; baseline SBP=159.9(14.3) mm Hg, DBP=99.9(5.2) mm Hg;
Trandolapril 2 mg: n=43(23 males,20 females); mean age=46(13) years; baseline SBP=161.1(13.1) mm Hg, DBP=99.8(5.9) mm Hg;
Placebo: n=44(18 males,26 females); mean age=50(7) years; baseline SBP=157.3(16.6) mm Hg, DBP=99.2(6.0) mm Hg |
| Interventions |
Trandolapril 0.5 mg once daily;
Trandolapril 1 mg once daily;
Trandolapril 2 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP and SD not reported; BP data from Figures 1 and 2, pp. S61‐S62; Jadad score=3; funding source= Roussel Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
